A Comparative Clinical Trial of Lymecycline
Abstract
Lymecycline (Tetracycline-L-mcthylene lysine ' Tetralysal ') has an antibacterial spectrum corresponding to that of the tetracycline it contains, but is 5,000 times more soluble in body fluids than tetracycline base, and 25 times more soluble than tetracycline hydrochloride. It remains in solution at all physiological pH values (De Cameri et al. 1961). Its rate of absorption from the isolated small intestine of white rats is higher than that of tetracycline hydrochloride (Mandeli et al. 1961). These pharmacological properties suggest that lymecycline should be better absorbed and better tolerated, particularly with regard to gastro-intestinal side-effects, than other forms of tetracycline commonly in use. The object of this trial was to assess the efficacy of, and incidence of side-effects in treatment with lymecycline given at the dose recommended by the manufacturers, and in comparison with the standard form of tetracycline used in this Hospital.
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.